Sulpiride - Analogs & derivatives
Research News and Information

Monday, November 23, 2009

Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.

6 Jul 2009 BACKGROUND: Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of ... Read more...

The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.

29 Jun 2009 Atypical antipsychotics have been reported to induce or exacerbate obsessive-compulsive symptoms (OCS) in patients with schizophrenia. We report the development of de novo obsession induced by sequential treatment with risperidone, aripiprazole, and ... Read more...

Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation.

29 Jun 2009 This study presents results of a 1-year follow-up investigation of the causal model of insight in schizophrenia using a subsample of acute patients starting or switching to amisulpride included in an earlier study. Our causal model of insight based ... Read more...

Latest indexed articles for 'Sulpiride - Analogs & derivatives'

These are the very latest articles for this heading:

• Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. 6 Jul 2009
• The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. 29 Jun 2009
• Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation. 29 Jun 2009
• Targeting cognition in schizophrenia research: from etiology to treatment. 30 May 2009
• Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. 29 Apr 2009
• Akathisia and second-generation antipsychotic drugs. 29 Apr 2009
• Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. 29 Apr 2009
• Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. 30 Mar 2009
• Amisulpride treatment for clozapine-induced sialorrhea. 30 Mar 2009
• Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. 30 Mar 2009
• Neuroleptics: necrotising enterocolitis. 30 Mar 2009
• Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. 30 Mar 2009
• Successful treatment with amisulpride for the progression of olfactory reference syndrome to schizophrenia. 13 Feb 2009
• Combination therapy of levosulpiride and lamotrigine associated with tardive dyskinesia. 30 Jan 2009
• Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study. 30 Jan 2009
• Comparative bioavailability study of amisulpride tablets in healthy Indian volunteers. 30 Dec 2008
• Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study. 30 Dec 2008
• Tardive dyskinesia in a patient treated with quetiapine. 30 Dec 2008
• Amisulpride-induced tardive dyskinesia and possible association of dyskinesia with hypothyroidism. 30 Dec 2008
• Hyperpigmentation with amisulpride. 30 Dec 2008

See a longer list of these articles.

Technical information about 'Sulpiride'

Definition: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)

Chemical name: Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-

Registry Number: 15676-16-1

Descriptor UI: D013469

Alternative terms: Sulpiride; Sulperide; Arminol; Krewel Brand of Sulpiride; Deponerton; Meresa; Vertigo-Meresa; Vertigo Meresa; Dolorgiet Brand of Sulpiride; Desisulpid; Desitin Brand of Sulpiride; Digton; Areu Brand of Sulpiride; Dogmatil; Dolmatil; Sanofi-Synthelabo Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Allphar Brand of Sulpiride; Eglonyl; Ekilid; Hoechst Brand of Sulpiride; Guastil; Uriach Brand of Sulpiride; Lebopride; Spyfarma Brand of Sulpiride; neogama; vertigo-neogama; vertigo neogama; Hormosan Brand of Sulpiride; Pontiride; Psicofarma Brand of Sulpiride; Psicocen; Centrum Brand of Sulpiride; Sulpitil; Pharmacia Brand of Sulpiride; Sulpivert; Hennig Brand of Sulpiride; Sulpor; Rosemont Brand of Sulpiride; Sulp; Hexal Brand of Sulpiride; Tepavil; Almirall Brand of Sulpiride; Synédil; Erempharma Brand of Sulpiride; Aiglonyl; Fumouzer Brand of Sulpiride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Antagonists; Antidepressive Agents, Second-Generation; Antipsychotic Agents;

Tree Number: D02.065.277.866; D02.241.223.100.120.866;

History Note: 74